



WORKSHOP THOMSON REUTERS TOOLS FOR DRUG DISCOVERY & BUSINESS DEVELOPMENT

WEDNESDAY, MAY 18

VENUE: **PARC CIENTIFIC BARCELONA**
c/ Baldiri Reixac, 4, 08028 Barcelona
Tower I, 3rd Floor, Room 4

AGENDA

9:00 – 9:20 **REGISTRATION**

9:20 – 9:30 **INTRODUCTIONS**

Yamina Hakem, Account Consultant, Thomson Reuters

9:30 – 10:45 **“ADVANCELL’S EXPERIENCE WITH THE THOMSON REUTERS INTEGRITY AND THOMSON REUTERS PHARMA TOOLS”**
A discussion surrounding the practical use of *Thomson Reuters Integrity*SM and *Thomson Reuters Pharma*TM in tandem, and the benefits of this method.

- Dr. Clara Campas-Moya, Executive VP, Advancell Therapeutics
- Celine Demange, Account Consultant, BD&L, Thomson Reuters
- Yamina Hakem, Account Consultant, BioChem, Thomson Reuters

10:45 – 11:15 **BREAK**

11:15 – 11:45 **“REGULATION OF THE RETINAL TRANSCRIPTOME BY AXONAL INJURY”**

Dr. Marta Agudo-Barriuso, Unidad de Investigación (Research Unit), Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

11:45 – 12:15 **“INTEGRATED ANALYSIS OF DISTINCT MOLECULAR AND PHENOTYPIC DATA TYPES IN DISEASE AND XENOBIOTIC RESPONSE MODELING”**

The integration of data on the functional consequences of sequence variation to the systems biology circuit model will be critical to complete understanding of system malfunction or failure in disease or toxicity, and to the successful implementation of personalized medicine. Gross damage to the circuitry by removal or functional impairment of certain components may impact the functioning of the circuit. Individual differences in the system, arising through sequence variations in the DNA template for individual components, also may affect the response of the circuit to normal stimuli or to xenobiotic interference. These variations manifest as different susceptibilities to disease, responses to therapeutic intervention or risks of chemical toxicity.

Richard Brennan, PhD DABT, Director of Toxicology, GeneGo (a Thomson Reuters Business)

12:15 – 15:00 **DEMONSTRATIONS**

Thomson Reuters’ Team will be available for hands on presentation of the GeneGo, *Thomson Reuters Integrity* and *Thomson Reuters Pharma* tools.

APPOINTMENTS ARE AVAILABLE FROM 12:30 – 15:00

Please contact **Laura Brovold** at laura.brovold@thomsonreuters.com to schedule a 30 minute appointment to demo GeneGo’s pathway analysis tools with your specific question.

Please contact **Yamina Hakem** at yamina.hakem@thomsonreuters.com to schedule a 30 minute appointment to demo the *Thomson Reuters Integrity Drug Research & Development* tool.

Please contact **Celine Demange** at celine.demange@thomsonreuters.com to schedule a 30 minute appointment to demo the *Thomson Reuters Pharma Competitive Intelligence & Business Development* tool.



THOMSON REUTERS™



SEMINAR THOMSON REUTERS TOOLS FOR DRUG DISCOVERY & BUSINESS DEVELOPMENT

WEDNESDAY, MAY 18

VENUE: **PARC CIENTIFIC BARCELONA**
c/ Baldiri Reixac, 4, 08028 Barcelona
Tower I, 3rd Floor, Room 4

AGENDA

9:00 – 9:20 **REGISTRATION**

9:20 – 9:30 **INTRODUCTIONS**

Yamina Hakem, Account Consultant, Thomson Reuters

9:30 – 10:45 **“ADVANCELL’S EXPERIENCE WITH THE THOMSON REUTERS INTEGRITY AND THOMSON REUTERS PHARMA TOOLS”**
A discussion surrounding the practical use of *Thomson Reuters Integrity*SM and *Thomson Reuters Pharma*TM in tandem, and the benefits of this method.

- Dr. Clara Campas-Moya, Executive VP, Advancell Therapeutics
- Celine Demange, Account Consultant, BD&L, Thomson Reuters
- Yamina Hakem, Account Consultant, BioChem, Thomson Reuters

10:45 – 11:15 **BREAK**

11:15 – 11:45 **“REGULATION OF THE RETINAL TRANSCRIPTOME BY AXONAL INJURY”**

Dr. Marta Agudo-Barriuso, Unidad de Investigación (Research Unit), Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

11:45 – 12:15 **“INTEGRATED ANALYSIS OF DISTINCT MOLECULAR AND PHENOTYPIC DATA TYPES IN DISEASE AND XENOBIOTIC RESPONSE MODELING”**

The integration of data on the functional consequences of sequence variation to the systems biology circuit model will be critical to complete understanding of system malfunction or failure in disease or toxicity, and to the successful implementation of personalized medicine. Gross damage to the circuitry by removal or functional impairment of certain components may impact the functioning of the circuit. Individual differences in the system, arising through sequence variations in the DNA template for individual components, also may affect the response of the circuit to normal stimuli or to xenobiotic interference. These variations manifest as different susceptibilities to disease, responses to therapeutic intervention or risks of chemical toxicity.

Richard Brennan, PhD DABT, Director of Toxicology, GeneGo (a Thomson Reuters Business)

12:15 – 15:00 **DEMONSTRATIONS**

Thomson Reuters’ Team will be available for hands on presentation of the GeneGo, *Thomson Reuters Integrity* and *Thomson Reuters Pharma* tools.

APPOINTMENTS ARE AVAILABLE FROM 12:30 – 15:00

Please contact **Laura Brovold** at laura.brovold@thomsonreuters.com to schedule a 30 minute appointment to demo GeneGo’s pathway analysis tools with your specific question.

Please contact **Yamina Hakem** at yamina.hakem@thomsonreuters.com to schedule a 30 minute appointment to demo the *Thomson Reuters Integrity Drug Research & Development* tool.

Please contact **Celine Demange** at celine.demange@thomsonreuters.com to schedule a 30 minute appointment to demo the *Thomson Reuters Pharma Competitive Intelligence & Business Development* tool.



THOMSON REUTERS™